Short Interest in Redhill Biopharma Ltd. (NASDAQ:RDHL) Drops By 13.6%

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 28,626 shares, a drop of 13.6% from the February 12th total of 33,139 shares. Based on an average trading volume of 36,555 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.6% of the company’s shares are short sold. Approximately 0.6% of the company’s shares are short sold. Based on an average trading volume of 36,555 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Redhill Biopharma in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Redhill Biopharma Trading Down 0.6%

Shares of NASDAQ RDHL traded down $0.01 during midday trading on Wednesday, reaching $0.87. The company’s stock had a trading volume of 2,212 shares, compared to its average volume of 549,392. The stock has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.29. The stock has a market capitalization of $4.45 million, a price-to-earnings ratio of 0.00 and a beta of 4.91. Redhill Biopharma has a fifty-two week low of $0.80 and a fifty-two week high of $3.31.

Hedge Funds Weigh In On Redhill Biopharma

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC lifted its position in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,102 shares of the biotechnology company’s stock after buying an additional 68,280 shares during the quarter. Gagnon Securities LLC owned about 1.68% of Redhill Biopharma worth $89,000 as of its most recent SEC filing. 7.20% of the stock is currently owned by institutional investors.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.